MD, PhD. Oncólogo | Unidad de Cáncer de Mama y Ginecológico Hospital 12 de Octubre (Spain) | ESMO Young Oncologists Committee Chair
Joined May 2012
- Tweets 2,598
- Following 688
- Followers 4,577
- Likes 6,796
261 Photos and videos
Pinned Tweet
22 May 2020
¡¡¡¡Soy Doctor en Medicina!!!! 👨🏼🎓
89
31
1,500
🧬HER2DX assay will be integrated soon (🤞🏻) into clinical practice.
🏥This work aims to share our experience in @H12Octubre using HER2DX in daily care of patients with HER2 EBC.
#PrecisionMedicine meets #Personalizedcare
Jun 11
Happy to share our recently published work! mdpi.com/3929536 #mdpiijms - @IJMS_MDPI @Rodrosb @anamg_98
📰Implementation of HER2DX Scores into Treatment Decisions in Early-Stage HER2-Positive Breast Cancer.
🤔HER2DX influenced treatment decisions in over half of patients in routine clinical practice.
👇👇Take a look
2
5
823
Rodrigo Sánchez-Bayona retweeted
🔝 Enrique G. Billalabeitia y Rodrigo Sánchez-Bayona, oncólogos del #H12O, reciben sendas Becas @GileadSciences a la Investigación Biomédica.
🔬 Para un proyecto sobre tumores germinales y para cáncer de mama HER2 positivo avanzado.
🔗 c.madrid/hr9bn
#somosdel12
1
9
45
3,037
La mejor noticia que leerás hoy: por primera vez en años, un fármaco duplica la supervivencia en pacientes con cancer de páncreas
Presented at #ASCO26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM
@ASCO
ALT Graph from a study published in the New England Journal of Medicine on daraxonrasib versus chemotherapy for metastatic pancreatic cancer. The x-axis represents months, and the y-axis shows the percentage of patients alive. Two lines indicate survival rates: daraxonrasib (blue) and chemotherapy (gray). The bottom section lists patients at risk over time. Title and journal logo are included.
4
14
27
2,112
Rodrigo Sánchez-Bayona retweeted
May 27
📰 Portada de EL MUNDO del 28 de mayo
Ya disponible en Orbyt y en la edición digital con la mejor información
183
2,625
5,044
88,263
Rodrigo Sánchez-Bayona retweeted
May 27
Spanish Prime Minister Pedro Sánchez is battling a wave of corruption allegations against people close to him, including his wife, his brother and former prime minister José Luis Rodríguez Zapatero. ft.trib.al/sSLtlPj
357
3,184
6,871
195,252
Rodrigo Sánchez-Bayona retweeted
May 19
2
3
247
Rodrigo Sánchez-Bayona retweeted
May 16
No todos los ensayos clínicos empiezan en un laboratorio… algunos empiezan en un taller 🔬
Abrimos inscripciones para el XIII Taller de Diseño de Ensayos Clínicos para Jóvenes Investigadores en el que durante dos días, jóvenes profesionales trabajarán en equipo para dar forma a propuestas de ensayos en distintos subtipos de enfermedad, guiados por formadores expertos.
Coordinado por la Dra. Maria Vidal (@MVidalMD) y el Dr. Rodrigo Sánchez-Bayona (@Rodrosb), es una experiencia pensada para aprender diseño clínico desde dentro, con enfoque práctico y colaborativo.
🗓️ 17-18 Septiembre
📍 Barcelona
¿Te sumas? ¡Apúntate aquí! 🔗 gruposolti.org/tallereeccjr2…
#beSOLTI #cáncerdemama
1
1
5
382
Rodrigo Sánchez-Bayona retweeted
📰New international cohort study now out in @RO_GreenJournal 👉Radiation therapy management in BRCA1/2 carriers diagnosed with early #BreastCancer.
🔓pubmed.ncbi.nlm.nih.gov/4194…
✍️@BlondeauxEva @LucaVisani2 @florencecoussy1 @dimeglio_anto @ava_kwong @ElisaAgostinett @JyotiBajpai01 @judithbalmana @AnnPartridgeMD @drkellyphillips @angela_toss @fedrophd @CuiWanda @vitti10 @DrShelleyHwang @MariyaRozenblit @BelaMrinakova @Prof_Nadia_H @Rodrosb @matteolambe @Icro_Meattini
7
9
1,017
📣The first results of the PROCURE Project are now published
🔬translational study, 26 Spanish institutions, 292 patients treated with TDXd
🧬pharmacogenomic analysis of UGT1A1 variants and TDXd-emergent AEs
🔜Ongoing cohort, stay tuned for more!
sciencedirect.com/science/ar…
6
18
1,999
Rodrigo Sánchez-Bayona retweeted
May 12
📰 Today, #ESMOopen publishes the results of #PROCURE, a multicenter study involving more than 26 Spanish hospitals.
This analysis, conducted in 290 patients treated with TDXd, examines the role of variants in the UGT1A1 gene and their potential association with treatment toxicity, concluding that no differences in toxicity were observed among the different variants.
@Rodrosb, medical oncologist at @H12Octubre, member of the #SOLTIyoung committee and PI of PROCURE, further states that “the results open new lines of research on pneumonitis and specific biomarkers associated with this adverse event, in a cohort where the observed incidence was 11%.”
We have actively participated by centralizing data collection and statistical analysis for a collaborative project that already includes more than 300 patients from across Spain and continues to grow thanks to funding from an ISCIII FIS grant.
PROCURE also won the 2022 Health Research Award from the HNA Foundation and was recently a finalist among more than 170 nominations for the 2026 GEPAC Awards.
📰 Full article: sciencedirect.com/science/ar…
5
9
768
Science only advances through generating evidence, which can be sometimes frustrating.
Negative results do not mean wasting time. They mean lessons learned.
Expectations are not evidence.
Kudos to @PTarantinoMD 💪🏻
May 9
Quoting @VincentRK: Clinical trials:
Easy to criticize. Hard to do.
Five years ago there was absolutely no data on ADC sequencing.
There were two approved ADCs, T-DXd and SG
With different target, linker, pharmacokinetics and slightly different payload structure.
A clear unmet need in the post-T-DXd HER2 setting.
Could the two ADCs work one after the other and help patients with HER2 MBC?
Two ways to attempt answering this question.
The faster, yet imperfect one: retrospective studies. We tried.
We (and others) analyzed data from hundreds of real-world patients across the US.
Presented and published our findings. academic.oup.com/jnci/articl…
Important questions, though, require quality answers.
We concomitantly designed the trial.
In a way to stop it early, after only 27 patients, if the answer was “not sufficient activity”, to ensure patients safety.
We ran the trial, SATEEN. And can finally provide a prospective answer.
Five years in the making. Huge efforts from research staff from multiple centers and from the sponsor. Generous participation by 27 patients.
To obtain what I believe is a quality answer for an important clinical question.
Not the answer we were hoping for. But one we can build on in the next years.
Clinical trials:
Easy to criticize. Hard to do.
4
6
1,614
Really proud of @H12Octubre Medical Oncology residents! Well done @LolaRNogueira
Great days at #ESMOBreast26 Berlin!!
-Presenting our HER2DX clinical impact data📊
- Discussing lobular BC at the YO mentored clinical case session with Dr Nicholas Turner
Thanks @myESMO and the YOC for the opportunity and the grant, but also to @RSanchezBayona for the support!
1
2
9
1,299
Rodrigo Sánchez-Bayona retweeted
May 7
SOLTI team at #ESMOBreast26 🚀
Halfway through the congress, we’ve already shared great discussions, exchanged new ideas, and gathered plenty of learnings along the way.
Together we accelerate the future of cancer research.
#beSOLTI
#ESMOBreastCancer #AnnualCongress
1
2
12
552
Rodrigo Sánchez-Bayona retweeted
Looking forward to a full day of @myESMO Young Oncologists activities at #ESMOBreast26 today — mentorship, clinical case discussions, and Vesalius talk
If you’re in Berlin, come join us for the discussions and connect with colleagues!
@myESMO
@DFCI_BreastOnc
@OncoAlert
7
9
1,012
Rodrigo Sánchez-Bayona retweeted
May 6
10) Impact of HER2DX testing for multidisciplinary care in a comprehensive cancer center
2
9
23
2,322
Rodrigo Sánchez-Bayona retweeted
👏 El Proyecto PROCURE de Rodrigo Sánchez-Bayona, oncólogo #H12O, finalista en los Premios @GEPAC_
✅ Analiza las variantes genómicas y el riesgo de toxicidad en pacientes con cáncer de mama, por el fármaco trastuzumab-deruxtecan.
⏩ c.madrid/8bdlw
#somosdel12
13
26
1,157
Rodrigo Sánchez-Bayona retweeted
AI is transforming oncology across research and clinical care
Join us for this @myESMO #YO4YO session focused on the critical evaluation and collaborative use of AI-powered tools
May 4 | 15:00–16:00 CEST
@OncoAlert @DFCI_BreastOnc @DanaFarber @KloftMaximilian @Rodrosb
Apr 29
Are you interested in #AI-powered tools in #oncology?
Join the #YO4YO Session w/ @GuiNaderMarta, @MaximilianKloft, @mihaela_aldea & @rdienstmann
📌 How to Evaluate and Collaborate on AI-Powered Tools in Oncology
#ESMOYOC
📅4 May 15:00-16:00 CEST
🔗 ow.ly/M9gC50YQqbu
9
15
3,703
Rodrigo Sánchez-Bayona retweeted
Apr 25
Rodrigo Sanchez Bayona on PROCURE Project Named Finalist at GEPAC Awards
@Rodrosb
oncodaily.com/voices/rodrigo…
#OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedTwitter
1
5
187
Rodrigo Sánchez-Bayona retweeted
Apr 17
SOLTI NEXUS 2026: Ahead of time. Now a reality.
Over two days in Madrid, our annual event brought together more than 170 researchers, clinicians, and innovators to connect, exchange ideas, and explore how AI is transforming the future of breast cancer research and care.
Key highlights from the meeting included the growing impact of integrating clinical, molecular, and imaging data to enhance precision in treatment selection and to improve the design of clinical trials. In parallel, artificial intelligence is already beginning to optimize key aspects of trial execution, particularly in the identification of eligible patients.
Special thanks to our coordinators: Dr. Rodrigo Dienstmann (VHIO, Barcelona), Dr. Mafalda Oliveira (Hospital Vall d’Hebron / VHIO, Barcelona), Dr. Kino Gavila (IVO, Valencia), Dr. Rodrigo Sanchez Bayona (Hospital 12 de Octubre, Madrid)
A huge thank you to all our speakers: Dr. Alexandre Yazigi (Resilience), Dr. Ignacio H. Medrano (Savana), Dra. Raquel Pérez (VHIO, Barcelona), Dra. Federica Corso (Instituto Nazionale dei Tumori di Milano), Dr. Francisco Miguel Torres Grande, PhD, EMBA(Owkin), Dr. Max Hardy-Werbin (Trailing Health), Dr. Jose Aneiros-Fernández (HT Médica, Granada), Dra. Nuria Ribelles (Hospital Universitario Virgen de la Victoria, Málaga), and inigo de miguel (Universidad del País Vasco)
🤝 And to everyone who supported this initiative to advance breast cancer research: @pfizer_spain, @NovartisSpain, @GileadOncology, @roche_es, @MSDEspana, @drreddys, @AstraZenecaES, @DaiichiSankyoES, @Stemline, @ExactSciencesPO, @EliLillyandCo and @JazzPharma.
A new meeting point is here to stay and this is just the beginning. See you in 2027!
Read more 🔗 gruposolti.org/la-inteligenc…
#beSOLTI #SOLTINexus #breastcancer
1
1
4
337